Get alerts
Closed

Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)

Posted
May 4, 2026
Closes
July 10, 2026
Award ceiling
$4,000,000
Program funding
$6,000,000
Cost sharing
No
Instrument
Cooperative Agreement
Assistance listing
93.867, 93.121, 93.846
Category
Health
Archives
September 8, 2026

Program funding history

Awards made under Assistance Listing 93.867 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$689M
FY2025 obligated
$696.7M
FY2026 (to date) obligated
$464.3M
Awards in window
3,418

Top recipients: The Johns Hopkins University, The Leland Stanford Junior University, Regents of the University of California, San Francisco, the, Jaeb Center for Health Research Foundation, Inc., Duke University

Source: USAspending.gov · refreshed August 2026

This opportunity is closed. Applications are no longer accepted. Similar open grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

This Notice of Funding Opportunity (NOFO) solicits cooperative agreement research applications to support a multidisciplinary program titled "Accelerating Product Excellence in Innovation and for Clinical Adoption" (APEx), that will facilitate advancement of promising strategies and products for tissue engineering and regenerative medicine (TE/RM). APEx will be composed of Resource Centers (RCs) and associated Interdisciplinary Translational Projects (ITPs) in the area of therapeutics (including adult stem cell-based treatments), sensors, and diagnostics. RCs will capitalize on their available clinical, scientific, industrial, regulatory and commercialization expertise, to deliver technical support, research capacity, administrative infrastructure and regulatory and commercialization support to the ITPs and guide them to complete pre-clinical studies toward initiation of clinical trials. During this funding cycle, APEx will complete validation, manufacturing, and preclinical testing of the most promising products, which may include, but are not limited to products for detecting or treating tissue damage caused by congenital defect, traumatic injury, or chronic disease. Products that support early detection of chronic pathologies, monitoring of validated biomarkers of health or disease, as well as approaches to reduce or prevent resulting damage, are especially encouraged. The outcome of APEx will be TE/RM products with their regulatory approvals in place for first-in-human studies, along with associated clinical study protocols, and synthesis and manufacturing protocols ready for initiation of clinical trials.

Who can apply

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.

View on Grants.gov

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get an alert the day a matching federal grant posts: we read every new Grants.gov posting and score it, personalized to your organization. Free for 30 days, then $19/mo founding rate locked for life — the rate holds while your subscription stays active (Terms). Card required, cancel any time before day 31.

See pricing